Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM-SPIRE in House Dust Mite-Induced Rhinoconjunctivitis
NCT02150343Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Sep 2014
- Primary completion
- Apr 2017
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 8
01
Overview
A Phase 2 trial of HDM-SPIRE in House Dust Mite-Induced Allergic Rhinoconjunctivitis (HDM-ARC), sponsored by NIOX Group. Started Sep 2014; status: completed.
02
Drugs
HDM-SPIRE
03
Conditions
House Dust Mite-Induced Allergic Rhinoconjunctivitis (HDM-ARC)
Beyond the preview
Go deeper on NCT02150343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02150343.